# Small Cell Lung Cancer ( SCLC ) FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/small-cell-lung-cancer-sclc

> 6 upcoming FDA catalysts in small Cell Lung Cancer ( SCLC ): alisertib (PBYI) on Mar to Jun 2028 (topline data readout); alisertib (PBYI) on March 2028 (primary completion); IMDELLTRA® (tarlatamab, AMGN) on Aug to Nov 2029 (topline data readout); IMDELLTRA® (tarlatamab, AMGN) on August 2029 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar to Jun 2028 | [Alisertib topline data readout](https://sec-api.dev/pdufa/alisertib) | PBYI | Small Cell Lung Cancer ( SCLC ) | scheduled | "NCT07465757 (A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07465757)) |
| March 2028 | [Alisertib primary completion](https://sec-api.dev/pdufa/alisertib) | PBYI | Small Cell Lung Cancer ( SCLC ) | scheduled | "NCT07465757 (A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Puma Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07465757)) |
| Aug to Nov 2029 | [IMDELLTRA® (tarlatamab) topline data readout](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small Cell Lung Cancer (SCLC) | scheduled | "NCT06745323 (A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-08-10 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06745323)) |
| August 2029 | [IMDELLTRA® (tarlatamab) primary completion](https://sec-api.dev/pdufa/tarlatamab) | AMGN | Small Cell Lung Cancer (SCLC) | scheduled | "NCT06745323 (A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-08-10 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06745323)) |
| Jun to Sep 2030 | [PF-08634404 topline data readout](https://sec-api.dev/pdufa/pf-08634404) | PFE | Small Cell Lung Cancer (SCLC) | scheduled | "NCT07226999 (Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-06-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226999)) |
| June 2030 | [PF-08634404 primary completion](https://sec-api.dev/pdufa/pf-08634404) | PFE | Small Cell Lung Cancer (SCLC) | scheduled | "NCT07226999 (Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-06-14 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226999)) |

## Drugs

- [Alisertib](https://sec-api.dev/pdufa/alisertib) (PBYI)
- [IMDELLTRA® (tarlatamab)](https://sec-api.dev/pdufa/tarlatamab) (AMGN)
- [PF-08634404](https://sec-api.dev/pdufa/pf-08634404) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/small-cell-lung-cancer-sclc.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Small Cell Lung Cancer ( SCLC ) FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/small-cell-lung-cancer-sclc

```bibtex
@misc{secapidev_indications_small_cell_lung_cancer_sclc_20261116,
  title        = {Small Cell Lung Cancer ( SCLC ) FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/small-cell-lung-cancer-sclc}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_small_cell_lung_cancer_sclc_20261116","title":"Small Cell Lung Cancer ( SCLC ) FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/small-cell-lung-cancer-sclc","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
